Iconovo (ICO) Stock Overview
Develops and licenses inhalation medications in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ICO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Iconovo AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.18 |
| 52 Week High | SEK 9.02 |
| 52 Week Low | SEK 1.05 |
| Beta | 0.47 |
| 1 Month Change | 0.93% |
| 3 Month Change | 84.75% |
| 1 Year Change | -74.65% |
| 3 Year Change | -96.64% |
| 5 Year Change | -96.70% |
| Change since IPO | -93.94% |
Recent News & Updates
Recent updates
Should You Investigate Iconovo AB (publ) (STO:ICO) At kr6.68?
Sep 22
We're A Little Worried About Iconovo's (STO:ICO) Cash Burn Rate
Jul 06Here's Why We're Watching Iconovo's (STO:ICO) Cash Burn Situation
Jul 29Companies Like Iconovo (STO:ICO) Are In A Position To Invest In Growth
Nov 10We're Not Worried About Iconovo's (STO:ICO) Cash Burn
Jul 31Is Now The Time To Look At Buying Iconovo AB (publ) (STO:ICO)?
Jul 12Shareholder Returns
| ICO | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 4.8% | 2.1% | 1.5% |
| 1Y | -74.7% | -12.9% | 0.9% |
Return vs Industry: ICO underperformed the Swedish Medical Equipment industry which returned -12.9% over the past year.
Return vs Market: ICO underperformed the Swedish Market which returned 0.9% over the past year.
Price Volatility
| ICO volatility | |
|---|---|
| ICO Average Weekly Movement | 11.0% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.1% |
Stable Share Price: ICO's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ICO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 27 | Johan Waborg | www.iconovo.se |
Iconovo AB (publ) develops and licenses inhalation medications in Sweden. The company offers ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone Nasal single-dose dry powder inhaler for nasal use. It serves generic companies.
Iconovo AB (publ) Fundamentals Summary
| ICO fundamental statistics | |
|---|---|
| Market cap | SEK 106.12m |
| Earnings (TTM) | -SEK 43.52m |
| Revenue (TTM) | SEK 19.39m |
Is ICO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICO income statement (TTM) | |
|---|---|
| Revenue | SEK 19.39m |
| Cost of Revenue | SEK 3.44m |
| Gross Profit | SEK 15.95m |
| Other Expenses | SEK 59.47m |
| Earnings | -SEK 43.52m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 24, 2025
| Earnings per share (EPS) | -0.82 |
| Gross Margin | 82.27% |
| Net Profit Margin | -224.44% |
| Debt/Equity Ratio | 0% |
How did ICO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/20 17:35 |
| End of Day Share Price | 2025/08/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Iconovo AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lars Hevreng | Danske Bank |
| Ludvig Svensson | DNB Carnegie Commissioned Research |
| Gustaf Meyer | Redeye |